Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
Deepak L. Bhatt,Marcus Flather,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon-Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Liz Fabry-Ribaudo,Tingfei Hu,Eric J. Topol,Keith A.A. Fox,Charisma Investigators +24 more
Reads0
Chats0
TLDR
In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke, or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2007-05-15 and is currently open access. It has received 722 citations till now. The article focuses on the topics: Clopidogrel & Stroke.read more
Citations
More filters
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
Patrick T. O'Gara,Frederick G. Kushner,Deborah D. Ascheim,Donald E. Casey,Mina K. Chung,James A. de Lemos,Steven M. Ettinger,James C. Fang,Francis M. Fesmire,Barry A. Franklin,Christopher B. Granger,Harlan M. Krumholz,Jane A. Linderbaum,David A. Morrow,L. Kristin Newby,Joseph P. Ornato,Narith N. Ou,Martha J. Radford,Jacqueline E. Tamis-Holland,Carl L. Tommaso,Cynthia M. Tracy,Y. Joseph Woo,David Zhao +22 more
TL;DR: The 2017-18 FAHA/FACC/FAHA Education and Research Grants will be focused on advancing the profession’s understanding of central nervous system disorders and the management of post-traumatic stress disorder.
Journal ArticleDOI
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Gilles Montalescot,Udo Sechtem,Stephan Achenbach,Felicita Andreotti,Chris Arden,Andrzej Budaj,Raffaele Bugiardini,Filippo Crea,Thomas Cuisset,Carlo Di Mario,J. Rafael Ferreira,Bernard J. Gersh,Anselm K. Gitt,Jean-Sébastien Hulot,Nikolaus Marx,Lionel H. Opie,Matthias Pfisterer,Eva Prescott,Frank Ruschitzka,Manel Sabaté,Roxy Senior,David P. Taggart,Ernst E. van der Wall,Christiaan J. Vrints,José Luis Zamorano,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Veronica Dean,Christi Deaton,Çetin Erol,Robert Fagard,Roberto Ferrari,David Hasdai,Arno W. Hoes,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Patrizio Lancellotti,Aleš Linhart,Petros Nihoyannopoulos,Massimo F Piepoli,Piotr Ponikowski,Per Anton Sirnes,Juan Tamargo,Michal Tendera,Adam Torbicki,William Wijns,Stephan Windecker,Marco Valgimigli,Marc J. Claeys,Norbert Donner-Banzhoff,Herbert Frank,Christian Funck-Brentano,Oliver Gaemperli,José Ramón González-Juanatey,Michalis Hamilos,Steen Husted,Stefan James,Kari Kervinen,Steen Dalby Kristensen,Aldo P. Maggioni,Axel R. Pries,Francesco Romeo,Lars Rydén,Maarten L. Simoons,Ph. Gabriel Steg,Adam Timmis,Aylin Yildirir +68 more
TL;DR: The If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction is evaluated as well as patients with Diabetes mellitus for Optimal management of Multivessel disease.
Journal ArticleDOI
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
Stephan D. Fihn,Julius M. Gardin,Jonathan Abrams,Kathleen Berra,James C. Blankenship,Apostolos P. Dallas,Pamela S. Douglas,JoAnne M. Foody,Thomas C. Gerber,Alan L. Hinderliter,Spencer B. King,Paul Kligfield,Harlan M. Krumholz,Raymond Y. Kwong,Michael J. Lim,Jane A. Linderbaum,Michael J. Mack,Mark A. Munger,Richard L. Prager,Joseph F. Sabik,Leslee J. Shaw,Joanna D. Sikkema,Craig R. Smith,Sidney C. Smith,John A. Spertus,Sankey V. Williams +25 more
TL;DR: A Report of the American College of Cardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines, and the AmericanCollege of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for CardiovascularAngiography and Interventions, and Society of ThorACic Surgeons
Journal ArticleDOI
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
Marco Valgimigli,Héctor Bueno,Robert A. Byrne,Jean-Philippe Collet,Francesco Costa,Anders Jeppsson,Peter Jüni,Adnan Kastrati,Philippe Kolh,Laura Mauri,Gilles Montalescot,Franz-Josef Neumann,Mate Petricevic,Marco Roffi,Philippe Gabriel Steg,Stephan Windecker,José Luis Zamorano,Glenn N. Levine,Lina Badimon,Pascal Vranckx,Stefan Agewall,Felicita Andreotti,Elliott M. Antman,Emanuele Barbato,Jean-Pierre Bassand,Raffaele Bugiardini,Mustafa Cikirikcioglu,Thomas Cuisset,Michele De Bonis,Victora Delgado,Donna Fitzsimons,Oliver Gaemperli,Nazzareno Galiè,Martine Gilard,Christian W. Hamm,Borja Ibanez,Bernard Iung,Stefan James,Juhani Knuuti,Ulf Landmesser,Christophe Leclercq,Maddalena Lettino,Gregory Y.H. Lip,Massimo F Piepoli,Luc Pierard,Markus Schwerzmann,Udo Sechtem,Iain A. Simpson,Miguel Sousa Uva,Eugenio Stabile,Robert F. Storey,Michal Tendera,Frans Van de Werf,Freek W.A. Verheugt,Victor Aboyans,Antonio Coca,I M Coman,Veronica Dean,Victoria Delgado,Gerhard Hindricks,Hugo A. Katus,Patrizio Lancellotti,Theresa McDonagh,Piotr Ponikowski,Dimitrios J. Richter,Evgeny Shlyakhto,Franz Xaver Roithinger,Farid Aliyev,Valeriy Stelmashok,Walter Desmet,Arman Postadzhiyan,Georgios P Georghiou,Zuzana Motovska,Erik Lerkevang Grove,Toomas Marandi,Tuomas Kiviniemi,Sasko Kedev,Steffen Massberg,Dimitrios Alexopoulos,Róbert Gábor Kiss,Ingibjorg Jona Gudmundsdottir,Eugene P. McFadden,Eli I. Lev,Leonardo De Luca,Akhmetzhan Sugraliyev,Edmond Haliti,Erkin M. Mirrakhimov,Gustavs Latkovskis,Birute Petrauskiene,Steve Huijnen,Caroline Jane Magri,Rhizlan Cherradi,Jurriën M. ten Berg,Jan Eritsland,Andrzej Budaj,Carlos Aguiar,Dmitry Duplyakov,Marco Zavatta,Nebojsa M Antonijevic,Zlatko Fras,Antonio Tello Montoliu,Christoph Varenhorst,Dimitri Tsakiris,Faouzi Addad,Sinan Aydogdu,Alexander Parkhomenko,Tim Kinnaird +106 more
TL;DR: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed in collaboration with EACTS is described in this paper.
Journal ArticleDOI
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Frederick G. Kushner,Mary M. Hand,Sidney C. Smith,Spencer B. King,Jeffrey L. Anderson,Elliott M. Antman,Steven R. Bailey,Eric R. Bates,James C. Blankenship,Donald E. Casey,Lee A. Green,Judith S. Hochman,Alice K. Jacobs,Harlan M. Krumholz,Douglass A. Morrison,Joseph P. Ornato,David L. Pearle,Eric D. Peterson,Michael A. Sloan,Patrick L. Whitlow,David O. Williams +20 more
TL;DR: A primary challenge in the development of clinical practice guidelines is keeping pace with the stream of new data on which recommendations are based as discussed by the authors, and the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) is to respond promptly to new evidence.
References
More filters
Journal ArticleDOI
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Salim Yusuf,Zhao F,Shamir R. Mehta,Susan Chrolavicius,Gianni Tognoni,K K Fox,Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators +6 more
TL;DR: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation, however, the risk of major bleeding is increased among patients treated with clopIDogrel.
Journal Article
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE).
TL;DR: Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death.
Journal ArticleDOI
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
Maarten L. Simoons,Eric J. Topol,Robert M. Califf,Frans Van de Werf,Paul W. Armstrong,Philip Edmund Aylward,G.I. Barbash,Eric R. Bates,A. Betriu,James Chesebro,J Col,David de Bono,JM Gore,Alan Guerci,John R. Hampton +14 more
TL;DR: The findings of this large-scale trial indicate that accelerated t-PA given with intravenous heparin provides a survival benefit over previous standard thrombolytic regimens.
Journal Article
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
TL;DR: The CAPRIE trial as discussed by the authors evaluated the relative efficacy of clopidogrel and aspirin in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed.
Journal ArticleDOI
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Steven R. Steinhubl,Peter B. Berger,J. Tift Mann,Edward T.A. Fry,Augustin DeLago,Charles Wilmer,Eric J. Topol +6 more
TL;DR: Following PCI, long-term clopidogrel therapy significantly reduced the risk of adverse ischemic events and subgroup analyses suggest that longer intervals between the loading dose and PCI may reduce events.